BioStem Technologies, Inc. reported preliminary financial results for the second quarter of 2025, including net revenue of $49.3 million and positive adjusted EBITDA of $2.5 million. The company appointed Brandon Poe as CFO and completed enrollment in a clinical trial for diabetic foot ulcers.

Despite facing challenges from increased competition and reimbursement uncertainty, BioStem Technologies remains confident in the clinical value of its products. The company is working towards uplisting to Nasdaq and evaluating the audit process with its new CFO, Brandon Poe, to achieve strategic objectives.

Financial results for the second quarter of 2025 showed a 34% decrease in net revenue compared to the same period in 2024, with gross profit at 98.6% of net revenue. Operating expenses decreased due to lower revenue, impacting adjusted EBITDA, which was reported at $2.5 million.

BioStem Technologies’ consolidated balance sheets for June 30, 2025, showed total assets of $112.6 million and total liabilities of $64.5 million. The company’s stockholders’ equity was at $48.1 million, reflecting its financial position.

Adjusted EBITDA, a non-GAAP financial measure used by BioStem, was reported at $2.5 million for the second quarter of 2025. This measure helps evaluate the company’s operating performance and trends, providing useful information to investors and enhancing transparency in financial metrics.

Read more at GlobeNewswire: BioStem Technologies Reports Preliminary Second Quarter